GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:KITE
Delisted

Kite Pharma Fund Forecast

$179.79
+0 (+0%)
At Close: Oct 19, 2017
RSI low/high Values: [ 25 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Red day on Thursday for Kite Pharma
(Updated on Oct 19, 2017)

Hold candidate since Oct 12, 2017 PDF

No changes to the price of Kite Pharma fund on the last trading day (Thursday, 19th Oct 2017). During the last trading day the fund fluctuated 0% from a day low at $179.79 to a day high of $179.79. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The fund has broken the wide and strong rising short-term trend down. This signalizes a slower rate of rising, but may also be an early warning about a possible trend shift. Due to the trend being broken there will now be resistance at the bottom line of the trend at $188.05. A reaction back to this level may hold a second chance to get out before further falls.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

KITE Signals & Forecast

The Kite Pharma fund holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $179.79 and $179.28. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Friday, September 29, 2017, and so far it has fallen -0.0111%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Kite Pharma fund

Kite Pharma finds support from accumulated volume at $178.05 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the fund tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the fund During the last day, the fund moved $0 between high and low, or 0%. For the last week the fund has had daily average volatility of 0%

Our recommended stop-loss: $172.60 (-4.00%) (This fund has low daily movements and this gives low risk. There is a sell signal from a pivot top found 14 days ago.)

Trading Expectations (KITE) For The Upcoming Trading Day Of Friday 20th

For the upcoming trading day on Friday, 20th we expect Kite Pharma to open at $179.79, and during the day (based on 14 day Average True Range), to move between $179.06 and $180.52, which gives a possible trading interval of +/-$0.731 (+/-0.41%) up or down from last closing price. If Kite Pharma takes out the full calculated possible swing range there will be an estimated 0.81% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $179.81 (0.01%) than the support at $178.05 (0.97%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Kite Pharma fund A Buy?

Kite Pharma holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: 0.438 Hold/Accumulate Unchanged

Predicted Opening Price for Kite Pharma of Friday, October 20, 2017

Fair opening price October 20, 2017 Current price
$179.79 ( 0%) $179.79

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for KITE

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 179.79 .
R2 179.79 .
R1 179.79 .
Current price: 179.79
Support S1 179.79 .
S2 179.79 .
S3 179.79 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 179.81 0.0111 %
Current price 179.79
Support S1 178.05 -0.97%
S2 177.98 -1.01%
S3 177.95 -1.02%

FAQ

What is the symbol for Kite Pharma Fund and on which exchange is it traded?
The symbol for Kite Pharma is KITE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Kite Pharma Fund?
Kite Pharma holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Kite Pharma Fund?
Kite Pharma Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Kite Pharma Fund.

What's the current price of Kite Pharma Fund?
As of the end of day on the 2017-10-19, the price of an Kite Pharma (KITE) share was $179.79.

What is the 52-week high and low for Kite Pharma Fund?
The 52-week high for Kite Pharma Fund is $179.95 and the 52-week low is $39.82.
Click to get the best stock tips daily for free!

About Kite Pharma

Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 2 clinical trials for the treatmen... KITE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT